Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia

Ane Uranga, Pedro Pablo Espana, Alberto Capelastegui, Rosa Díez, Amaia Bilbao, Carmen Mar, Edurne Bereciartua
European Respiratory Journal 2013 42: 5042; DOI:
Ane Uranga
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pedro Pablo Espana
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Capelastegui
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Díez
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amaia Bilbao
2Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n,Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Mar
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edurne Bereciartua
1Pneumology, Hospital of Galdakao, Galdakao, Barrio Labeaga s/n, Vizcaya, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background:

Recently, an extensive research has gone into identifying the predictive value of biomarkers for long term mortality in community-acquired pneumonia (CAP).

Objective:

The aim of this study was to evaluate the utility of inflammatory biomarkers measured on admission to predict mortality in patients with CAP.

Methods:

We prospectively included patients over 18 years old for a period of one year. Procalcitonin (PCT), C reactive protein (CRP) and Pro adrenomedullin (ProADM) levels were were compared according to in-hospital mortality, 30, 90 and 180-day mortality, and 1 year mortality, by means of the nonparametric Wilcoxon test. In addition, the predictive accuracy of each biomarker for mortality was analysed by means of logistic regression models, and the AUC was used to measure the predictive ability of each biomarker.

Results:

A total of 610 patients with diagnosis of CAP were included in our study and samples for biomarkers could be extracted in 491 of them. PCT and ProADM levels were significantly higher for short, medium and long term mortality. ProADM was the best biomarker in predicting complications. Figure 1 shows the results of the predictive ability of each biomarker for mortality.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Conclusions:

ProADM is a powerful tool not only for the prediction of short and medium mortality, but also for long term mortality.

  • Pneumonia
  • Biomarkers
  • Sepsis
  • © 2013 ERS
Previous
Back to top
Vol 42 Issue Suppl 57 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia
Ane Uranga, Pedro Pablo Espana, Alberto Capelastegui, Rosa Díez, Amaia Bilbao, Carmen Mar, Edurne Bereciartua
European Respiratory Journal Sep 2013, 42 (Suppl 57) 5042;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia
Ane Uranga, Pedro Pablo Espana, Alberto Capelastegui, Rosa Díez, Amaia Bilbao, Carmen Mar, Edurne Bereciartua
European Respiratory Journal Sep 2013, 42 (Suppl 57) 5042;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
  • LATE-BREAKING ABSTRACT: Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?
  • LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients
Show more 1.1 Clinical Problems

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society